Pharmaceutical Executive: October 2023

Industry experts discuss the relationship between digital and traditional (key) opinion leaders and how companies are adjusting their strategies to harness the unique brand engagement benefits each role can provide in driving better patient outcomes.

Stephen Rivera, vice president, global technical accounting advisory services and policy, Johnson & Johnson, capitalizes on his lively personality—and a courageous career journey—to bring people together to shape the future of biopharma.

Exploring the pharma and biotech financing, M&A, and stock market pictures through the first half of 2023—and implications for the future, as market challenges continue to weigh heavily in senior management decision-making.

A look at the intersection of rigorous compliance and ethical behavior: independent, charitable patient assistance foundations.

Payers won’t let these products break the bank.

Clinical studies are increasingly designed to satisfy evidentiary needs.

When you know it is coming—but it takes forever to get there.

How pharma companies can make justice and integrity a priority.

Effective engagement—from research to reimbursement—is key.

It’s with a heavy heart that I share my departure from Pharmaceutical Executive.® It’s hard to believe that one year ago (in September 2022) I began my journey with the team here and the publication (and with all of you!). First and foremost, a huge thank you to you, the reader, for trusting me to share content with you.

Click the title above for a link to open the Pharmaceutical Executive October 2023 issue in an interactive PDF format.